Antitrust Investigation

After a multi-year legal battle over a construction project ended in a total loss, Colleyville taxpayers are footing a $1.37 million bill.

Facing a shareholder revolt after a damning indictment, Supermicro launches a major probe into a $2.5B shadow trade scheme. Is it too little, too late?

Top sports law expert Gabe Feldman joins Emergetic Sports to implement Project Northstar, a radical plan to solve the financial crisis in college sports.

After a massive breach exposed sensitive genetic data, 23andMe's Canadian settlement is final. Learn what went wrong and how to claim your share.

A parent's multi-year legal battle over financial mismanagement has ended in a landmark settlement, forcing major governance and transparency reforms.

Richtech Robotics hires top-tier auditor CBIZ, citing a strategic shift, but SEC filings reveal a prior warning about a “material weakness” in controls.

Consumers overcharged for generic drugs may get cash from a new $17.8M settlement. Find out if you're eligible and how this fits into a larger legal war.

As regulators fine major ad platforms, PropellerAds' successful ISO 27001:2022 audit reaffirms its security commitment in a data-sensitive industry.

Actelion Pharmaceuticals settles a class action lawsuit for $65M, accused of illegally blocking a cheaper generic for its life-saving hypertension drug.

BRC Group Holdings announced a major debt reduction, but a history of late filings, shareholder dilution, and high-risk bets cast a shadow on its recovery.

New research shows a telehealth model boosting GLP-1 results to over 26% weight loss, but its reliance on unapproved compounded drugs raises safety flags.

Lawyers for Tirana's detained mayor accuse a U.S.-backed anti-graft unit of due process violations, urging Washington to intervene in the high-stakes case.

A petition filed with the Dept. of Commerce alleges a major railcar firm is evading duties on parts from China and Mexico, setting up a major trade battle.

After its Alzheimer's drug failed amidst controversy, Cassava Sciences rebrands as Filana Therapeutics, betting its future on a rare epilepsy disorder.

As Capricor prepares its Q4 earnings call, all eyes are on its DMD drug Deramiocel's FDA path, financial health, and next-gen exosome technology.

Investors drop their petition over Coupang's treatment, but the US government now plans a broader trade investigation into South Korea's digital practices.

Facing volatile markets, AVAX One pushes for regulatory clarity at the DC Blockchain Summit, aiming to legitimize Avalanche for institutional investors.

A new nicotine-free pouch powered by a caffeine metabolite enters the market, led by a controversial founder aiming to redefine focus and energy.

A new poll reveals overwhelming public opposition to a federal plan to stockpile glyphosate, fueled by billions in lawsuits and a retracted safety study.

A $1M deal offers a sliver of recovery for victims of the $71M William Jordan Ponzi scheme, putting custodian Kingdom Trust's alleged role in focus.